June 5, 2019
The Institute for Clinical and Economic Review is dashing patients’ hopes yet again.
August 9, 2018
An influential calculation of how new drugs impact annual spending is flawed – and patients may be paying the price in reduced access to innovative medicine.
June 8, 2018
Economists at the Institute for Clinical and Economic Review advise a whopping 77 percent price discount on new CFTR modulators for cystic fibrosis, according to a final evidence report. The drugs can “substantially improve patient health outcomes,” the group concedes, but their prices exceed ICER’s cost-effectiveness threshold. One manufacturer has called ICER’s analysis “a sham.”
March 23, 2018
If health plans heed a new report from the Institute for Clinical and Economic Review, patients with few options to treat their cystic fibrosis may soon have fewer still.
February 26, 2018
Waiting is a fact of life for patients with rare diseases such as cystic fibrosis.
Many of these men and women, whose disease causes wheezing and frequent lung infections, live waiting for new and effective medications. They have to delay activities due to symptoms that make breathing a struggle. They wait for treatment, fighting through health plan barriers such as prior authorization or awaiting the decision of opaque bureaucracies such as Medicaid pharmacy and therapeutics committees.
November 3, 2015
Widespread debate erupted several weeks ago when a pharmaceutical start-up bought and raised the price of a 60-year-old drug by 5,000 percent.
September 22, 2015
For patients, the immense value of a life-changing medication can be difficult to quantify.
